A pivotal trial of PM-359
Latest Information Update: 08 Oct 2024
Price :
$35 *
At a glance
- Drugs PM 359 (Primary)
- Indications Chronic granulomatous disease
- Focus Registrational; Therapeutic Use
- Sponsors Prime Medicine
- 08 Oct 2024 New trial record
- 30 Sep 2024 According to a Prime Medicine media release, company shows intentions to advance PM359 rapidly into a pivotal study.